Drug Trial Radar · NCT01474083
A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Sep 13, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
248
Actual
Start
Nov 2011
Primary completion
Aug 2012
Study completion Sep 2012
Sponsor
- Lead sponsor
- vTv TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to study the drug levels and biomarkers in the body and the safety of an investigational drug (GK1-399) in patients with Type 2 diabetes. Patients in the study will receive placebo for 1 week followed by 1 of 4 treatments for 6 weeks. One of the 4 treatments will be placebo, which does not contain an active ingredient. The study participation includes in-patient and out-patient days.
Conditions
- Type 2 Diabetes Mellitus
Interventions
GK1-399 (formerly TTP399)Drug
Treatment A: GK1-399 200 mg. Oral administration, twice per day.
GK1-399 (formerly TTP399)Drug
Treatment B: GK1-399 800 mg. Oral administration, once per day.
GK1-399 (formerly TTP399)Drug
Treatment C: GK1-399 800 mg. Oral administration, twice per day.
PlaceboDrug
Dose-matched placebo. Oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetic parameters of GK1-399 from plasma concentrationsTime frame: 52 time points over a 6 week period
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Forest Investigative Site 009
Little Rock, Arkansas
Forest Investigative Site 006
Chula Vista, California
Forest Investigative Site 002
DeLand, Florida
Forest Investigative Site 001
Miami, Florida
Forest Investigative Site 010
Overland Park, Kansas
Forest Investigative site 011
Saint Paul, Minnesota
Forest Investigative Site 005
Springfield, Missouri
Forest Investigative Site 003
Neptune City, New Jersey
Forest Investigative Site 008
Willingboro, New Jersey
Forest Investigative Site 007
New York, New York
Forest Investigative Site 004
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.